Read More Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate GNPX | Complete Genprex Inc. stock news by MarketWatch.
Whether you or somebody you know is afflicted by one of these diseases, you are a medical practioner interested in our treatment options, or you are an investor that has supported our fight, we want to keep you informed of our advancements. Find the latest Genprex, Inc. (GNPX) stock quote, history, news and other vital information to help you with your stock trading and investing. Genprex, Inc. is a clinical stage gene therapy company, which engages in the development of novel proprietary technology platform for the treatment of cancer. Genprex, Inc. (NASDAQ:GNPX) 2 of the analysts out of 2 who provided ratings for Genprex, Inc. stocks as a “buy” while 0 as overweight, 0 rated it as hold and 0 as sell. The simple moving average for the period of the last 20 days is 1.51% for GNPX stocks with the simple moving average of 74.79% for the last 200 days.Many brokerage firms have already submitted their reports for GNPX stocks, with Noble Capital Markets repeating the rating for GNPX shares by setting it to “Outperform”.
The average price we get from analysts is $6.50 which is -$3.15 below current price. Genprex, Inc. (NASDAQ:GNPX) went up by 3.96% from its latest closing price when compared to the 1-year high value of $7.03 and move down -123.17%, while GNPX stocks collected +0.64% of gains with the last five trading sessions. Get the latest Genprex, Inc. (GNPX) stock news and headlines to help you in your trading and investing decisions. Genprex, Inc. (NASDAQ:GNPX) went up by 3.96% from its latest closing price when compared to the 1-year high value of $7.03 and move down -123.17%, while GNPX stocks collected +0.64% of gains with the last five trading sessions.
Press Release reported on 06/29/20 that Genprex Added to Russell 3000(R) Index Find the latest news headlines from Genprex, Inc. Common Stock (GNPX) at Nasdaq.com. Genprex was added to the Russell 3000® Index after the market closed on Friday, June 26, 2020 as part of the 2020 Russell U.S. Indexes reconstitution. © 2020 © 2020 Genprex Inc. All Rights Reserved.
For up-to-the-minute company news delivered straight to your inbox, sign up for our email newsletter. Our technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options.We are developing gene therapies for patients with cancer and diabetes to bring new treatment options to large patient populations.
View real-time stock prices and stock quotes for a full financial overview. Stock analysis for Genprex Inc (GNPX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Our lead product candidate, GPX-001, is designed to be administered in combination with other therapies, including targeted therapies and immunotherapies, for non-small cell lung cancer.We have assembled a multidisciplinary team of executives and advisors with broad business experience in the biotech and pharmaceutical industries, and research and clinical experience at preeminent medical and academic institutions around the world. In oppose to the moving average for the last 50 days, trading by +28.57% upper at the present time.In the course of the last 5 trading sessions, GNPX went up by +0.64%, which changed the moving average for the period of 200 days to the total of +241.39% of gains for the stock in comparison to the 20-day moving average settled at $3.10.
GNPX currently has a short float of 12.84% and public float of 25.30M with average trading volume of 2.68M shares.GNPX stocks went up by 0.64% for the week, with the monthly drop of -2.78% and a quarterly performance of 47.54%, while its annual performance rate touched 166.95%.